Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

JW Therapeutics

Request full access

Shanghai based therapeutics platform

Pudong, ChinaFounded 2016Biotech & Life Sciences

About JW Therapeutics

JW Therapeutics (HKEx: 2126) operates as a clinical-stage biopharmaceutical company focused on cell-based immunotherapies for cancer patients in China. The company was established in February 2016 as a joint venture between WuXi AppTec and Juno Therapeutics (a Bristol Myers Squibb company) in Shanghai. This strategic partnership was designed to combine Juno's proficiency in Chimeric Antigen Receptor T-cell (CAR-T) technology with WuXi AppTec's local R&D, manufacturing capabilities, and market expertise in China.

The company's business model centers on the development, manufacturing, and commercialization of cell immunotherapy products. Its target clients are patients with hematological cancers and solid tumors, primarily within the Chinese market. Revenue is generated from the sale of its approved therapies. The company went public in 2020 via an IPO on the Hong Kong Stock Exchange. Co-founder Dr. James Li, who previously served as the founding general manager for Amgen in China and was a partner at Kleiner Perkins, led the company as CEO until July 2024. In July 2024, Min Liu, formerly the chief commercial officer at Innovent Biologics, was appointed CEO.

JW Therapeutics' lead product is Carteyva® (relmacabtagene autoleucel or relma-cel), an autologous anti-CD19 CAR-T therapy. This therapy involves genetically modifying a patient's own T-cells to recognize and attack cancer cells expressing the CD19 protein. In September 2021, Carteyva® received approval from China's National Medical Products Administration (NMPA) for treating adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This marked it as the first CAR-T product approved as a Category 1 biologics product in China. The company's product pipeline also includes JWCAR129, a CAR-T therapy targeting BCMA for the treatment of multiple myeloma, and it is expanding its research to cover solid tumors and autoimmune diseases through collaborations. To support its commercialization efforts, the company has established a 10,000-square-meter GMP manufacturing facility in Suzhou.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2016
Headquarters
Pudong, China
Employees
176
Open positions
10
Dealroom signal
93.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
IPOOther financing Nov 2020 $300M $300M Undisclosed —
SERIES BOther financing Jun 2020 $100M $400M Sequoia · Temasek · Oriza Holdings · ARCH Venture Partners —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowthEBITDAMargin
2026
2025
2024
2023
2022
2021 —
2020 — —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

JW Therapeutics website traffic

Latest recorded traffic for JW Therapeutics is 700 monthly website visits, down 50% over the last three months. JW Therapeutics's team grew 60% over the past year.

Latest monthly visits700 3-month web change-50% 1-year team growth+60%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

JW Therapeutics in the Pudong ecosystem

Live from Dealroom

The JW Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A11 investors entered at this stage

Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇳 China90.3%
🇺🇸 United States9.7%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about JW Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See JW Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.